Business Context and Reporting Period
This Form 8-K filing by Omeros Corporation (OMEROS CORP) reports a material event occurring on October 4, 2017. The filing details the resolution of patent litigation regarding the Company's drug OMIDRIA (phenylephrine and ketorolac injection) through a Settlement Agreement and consent judgment with Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the terms of a legal settlement rather than periodic financial performance.
Material Changes and Agreement Terms
- Patent Validity: Par acknowledged and confirmed the validity of six U.S. patents listed in the Orange Book for OMIDRIA (Nos. 8,173,707; 8,586,633; 9,066,856; 9,278,101; 9,399,040; and 9,486,406).
- Market Exclusivity: Par is prohibited from launching a generic version of OMIDRIA until the earlier of April 1, 2032, or a date determined by future licensing or legal judgments.
- Licensing and Royalties: Upon the "Entry Date," the Company granted Par a non-exclusive, non-sublicensable license to sell a generic version of OMIDRIA until the latest patent expiration (October 23, 2033). Par will pay the Company a royalty equal to 15% of its net sales of the generic product during this period.
Outlook, Risks, and Management Commentary
The settlement resolves the Company's patent litigation against Par, which arose from Par's Abbreviated New Drug Application. The agreement secures a potential future revenue stream via royalties while extending the effective market exclusivity of OMIDRIA. The filing notes that the Settlement Agreement contains representations and warranties made solely for the benefit of the contracting parties and does not provide other factual information about the Company.
Investor Verification Checklist
- Verify the specific terms of the Settlement Agreement filed as Exhibit 10.1.
- Confirm the exact list of patents validated and their individual expiration dates.
- Monitor the "Entry Date" conditions that could allow generic competition prior to April 1, 2032.
- Review the definition of "net sales" within the agreement to understand the royalty calculation basis.